Delving into the Latest Updates on Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd. with Synapse

Overview

1.评估本品在CD20阳性B细胞非霍奇金淋巴瘤患者中的耐受性和安全性，确定DLT、MTD。 2.评估本品在CD20阳性B细胞非霍奇金淋巴瘤患者中的药代动力学、药效动力学和免疫原性。 3.评估本品在CD20阳性B细胞非霍奇金淋巴瘤患者中的客观反应率。

[Translation]

1. Evaluate the tolerability and safety of this product in patients with CD20-positive B-cell non-Hodgkin's lymphoma, and determine the DLT and MTD. 2. Evaluate the pharmacokinetics, pharmacodynamics and immunogenicity of this product in patients with CD20-positive B-cell non-Hodgkin's lymphoma. 3. Evaluate the objective response rate of this product in patients with CD20-positive B-cell non-Hodgkin's lymphoma.

Start Date10 Apr 2018

Sponsor / Collaborator

Shanghai Pharmaceuticals Holding Co., Ltd.

[+1]

100 Clinical Results associated with Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Recombinant anti-CD20 humanized monoclonal antibody(Shanghai Pharmaceuticals Holding Co., Ltd.) ( CD20 )	CD20 Positive B-Cell Non-Hodgkin Lymphoma More	Pending